Selective CSF1R Inhibition for TAM Depletion Without CSF1 Elevation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CSF1R inhibitors used in cancer treatment suffer from off-target toxicity and significant increases in CSF1 levels due to ligand blockade, limiting their effectiveness and safety.
Innovation Solution
Development of a selective small-molecule CSF1R inhibitor, 2-(isopropylamino)-3-methyl-5-(6-methyl-5-((2-(1-methyl-1H-pyrazol-4-yl)pyridin-4-yl)oxy)pyridin-2-yl)pyrimidin-4(3H)-one, administered in specific dosing regimens to target tumor-associated macrophages (TAMs) and treat disorders like tenosynovial giant cell tumors and various cancers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If antibodies targeting CSF1R are used to achieve high specificity, then selectivity is improved, but plasma levels of CSF1 increase >10,000-fold due to blockade of clearance
Solution Approach 1:
The patent transitions from antibody-based inhibition to small-molecule inhibitor-based inhibition, fundamentally changing the mode of action. Small molecules like pexidartinib directly bind to and inhibit CSF1R kinase activity without blocking the CSF1 clearance pathway, thereby maintaining CSF1 levels at physiological concentrations while achieving selective CSF1R inhibition. This parameter change in the inhibition mechanism resolves the contradiction between specificity and CSF1 level elevation.
2Adaptability or versatility
If non-selective CSF1R inhibitors are used to achieve broad activity, then efficacy against multiple targets is improved, but off-target toxicity increases due to inhibition of KIT, PDGFRα/β and FLT3
Solution Approach 1:
The patent applies local quality by designing inhibitors with selective binding characteristics to CSF1R while avoiding off-target binding to KIT, PDGFRα/β, and FLT3. The chemical structure of pexidartinib and related compounds is optimized to interact specifically with the CSF1R binding pocket through unique molecular interactions, creating localized specificity at the target site. This selective binding approach maintains broad activity against CSF1R-expressing tumors while eliminating off-target toxicity to other kinases.
3Productivity
If surgical excision is used to treat tenosynovial giant cell tumor, then immediate tumor removal is achieved, but recurrence rate increases due to difficulty of marginal excision in diffuse form
Solution Approach 1:
The patent applies continuity of useful action by using CSF1R inhibitors to continuously suppress tumor cell proliferation and prevent recurrence after surgical excision. The inhibitors maintain therapeutic levels in the body over time, providing ongoing suppression of residual tumor cells that may remain after marginal excision. This continuous pharmacological intervention complements surgical treatment by addressing the recurrence problem through sustained inhibition of CSF1R signaling in diffuse-type tenosynovial giant cell tumor.
Data Source
AI summary
Described herein are methods of treating cancers and other tumors related to the decreased proliferation, the depletion, or the repolarization of tumor-associated macrophages (TAMs) and treatment of associated disorders, including tenosynovial giant cell tumor (TGCT) and diffuse-type tenosynovial giant cell tumor (DTGCT).